Phase III testing for nasal migraine drug

    Phase III testing has begun for a nasal treatment for migraine headaches.

    OptiNose Inc. of Yardley is moving forward with its bi-direction intranasal technology, the Philadelphia Business Journal reports.
    In short, the user exhales into a device that delivers the drug particles through one nasal passage, into the affected area and back out the other nasal passage.

    If things go accordingly, it might not be long before the company seeks FDA approval for the drug.

    Want a digest of WHYY’s programs, events & stories? Sign up for our weekly newsletter.

    It will take 126,000 members this year for great news and programs to thrive. Help us get to 100% of the goal.